Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Conditions
Interventions
LY3022855
Durvalumab
+1 more
Locations
14
United States
Sarah Cannon Research Institute at HealthOne
Denver, Colorado, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Winship Cancer Center Emory University
Atlanta, Georgia, United States
New York University Medical Center
New York, New York, United States
Columbia University College of Phys & Surgeons
New York, New York, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Start Date
June 16, 2016
Primary Completion Date
December 14, 2018
Completion Date
December 14, 2018
Last Updated
October 16, 2023
NCT05720117
NCT06898450
NCT06658951
NCT06625775
NCT05223608
NCT05719558
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions